Efficacy and safety of two-drug regimens for treatment of HIV in the central nervous system
AIDS
.
2020 Nov 1;34(13):1975-1977.
doi: 10.1097/QAD.0000000000002665.
Authors
Dana Gabuzda
1
,
Justin C McArthur
2
,
Scott L Letendre
3
Affiliations
1
Dana-Farber Cancer Institute, Boston, Massachusetts.
2
Johns Hopkins University School of Medicine, Baltimore, Maryland.
3
University of California, San Diego, San Diego, California, USA.
PMID:
33009012
PMCID:
PMC7536841
DOI:
10.1097/QAD.0000000000002665
No abstract available
Publication types
Research Support, N.I.H., Extramural
Comment
MeSH terms
Anti-HIV Agents* / adverse effects
HIV Infections* / drug therapy
HIV-1*
Humans
Nervous System
Substances
Anti-HIV Agents
Grants and funding
K24 MH097673/MH/NIMH NIH HHS/United States
P50 DA026306/DA/NIDA NIH HHS/United States
P30 MH075673/MH/NIMH NIH HHS/United States
P30 AI094189/AI/NIAID NIH HHS/United States
U24 MH100928/MH/NIMH NIH HHS/United States
UM1 AI068634/AI/NIAID NIH HHS/United States
R01 AG063659/AG/NIA NIH HHS/United States
P30 MH062512/MH/NIMH NIH HHS/United States
U01 MH083506/MH/NIMH NIH HHS/United States
R56 MH115853/MH/NIMH NIH HHS/United States
P01 MH105280/MH/NIMH NIH HHS/United States
UM1 AI068636/AI/NIAID NIH HHS/United States
R01 MH107345/MH/NIMH NIH HHS/United States
R25 MH080661/MH/NIMH NIH HHS/United States